Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.

1993, Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), JAMA, 269, 3015, 10.1001/jama.1993.03500230097036

Jones, 1991, Once-daily pravastatin in patients with primary hypercholesterolemia, Clin Cardiol, 14, 146, 10.1002/clc.4960140211

Illingworth, 1991, HMG CoA reducatase inhibitors, Curr Opin Lipidol, 2, 24, 10.1097/00041433-199102000-00006

Illingworth, 1994, A review of clinical trials comparing HMG CoA reductase inhibitors, Clin Ther, 16, 366

Weir, 1996, Comparison of the effects on quality of life and the efficacy and tolerability of lovastatin versus pravastatin, Am J Cardiol, 77, 475, 10.1016/S0002-9149(97)89340-X

1993, Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia, Am J Cardiol, 71, 1408, 10.1016/0002-9149(93)90601-8

1994, Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia, Cardiology, 85, 244, 10.1159/000176682

Douste-Blazy, 1993, Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia, Drug Invest, 6, 353, 10.1007/BF03259612

Illingworth, 1996, A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin, J Cardiovasc Pharmacol Ther, 1, 23, 10.1177/107424849600100105

Berger, 1996, A comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg in the treatment of primary hypercholesterolemia, J Cardiovasc Pharmacol Therapeut, 1, 101, 10.1177/107424849600100203

Jacotot, 1995, Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia, Am J Cardiol, 76, 54A, 10.1016/S0002-9149(05)80018-9

Schulte, 1996, Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolemic patients, Clin Drug Invest, 12, 119, 10.2165/00044011-199612030-00001

Lintott, 1993, Treating hypercholesterolemia with HMG CoA reductase inhibitors, Aust N Z J Med, 23, 381, 10.1111/j.1445-5994.1993.tb01439.x

Nawrocki, 1995, Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor, Arterioscler Thromb Vasc Biol, 15, 678, 10.1161/01.ATV.15.5.678

Gmerek A, Yang R, Bays H, Jones P, Knopp R, Littlejohn T, Schrott H, Black D. Atorvastatin causes a dose-dependent reduction in LDL-C and triglycerides. In: 66th Congress of the European Artherosclerosis Society, July 1996:212.

Davidson, 1997, Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia, Am J Cardiol, 79, 1475, 10.1016/S0002-9149(97)00174-4

Bertolini, 1997, Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia, Atherosclerosis, 130, 191, 10.1016/S0021-9150(96)06052-2

Dart, 1997, A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia, Am J Cardiol, 80, 39, 10.1016/S0002-9149(97)00280-4

Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499

Myers, 1989, The Centers for Disease Control—National Heart, Lung, and Blood Institute Lipid Standardization Program, Clin Lab Med, 9, 105, 10.1016/S0272-2712(18)30645-0

Steiner, 1981, Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Research Clinics’ methodology (abstr), J Clin Chem Clin Biochem, 19, 850

Steele, 1976, Enzymatic determinations of cholesterol in high density lipoprotein fractions prepared by a precipitation technique, Clin Chem, 22, 98, 10.1093/clinchem/22.1.98

Dunnett, 1955, A multiple comparison procedure for comparing several treatments with a control, J Am Stat Assoc, 50, 1096, 10.1080/01621459.1955.10501294

Blum, 1994, Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Am J Cardiol, 73, 3D, 10.1016/0002-9149(94)90626-2

Bradford, 1991, Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse events profile in 8245 patients with moderate hypercholesterolemia, Arch Intern Med, 151, 43, 10.1001/archinte.1991.00400010067008

Hsu, 1995, Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia, Ann Pharmacother, 29, 743, 10.1177/106002809502907-818

Dujovne, 1991, Expanded Clinical Evaluation of Lovastatin (EXCEL) study. IV. Additional perspectives on the tolerability of lovastatin, Am J Med, 91, 25S, 10.1016/0002-9343(91)90053-Z